September 17, 2018 M&A, Partnerships

BeiGene Selects GE Healthcare's Off-the-Shelf Biologics Factory to Boost its Manufacturing Capacity for Cancer Drugs

  BeiGene to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies   CHALFONT ST. GILES, UK and BEIJING, CHINA – 18 September 2018 – BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs... Read more

September 17, 2018 M&A, Partnerships

BeiGene Selects GE Healthcare’s Off-the-Shelf Biologics Factory to Boost its Manufacturing Capacity for Cancer Drugs

CHALFONT ST. GILES, UK and BEIJING, CHINA – 18 September 2018 – BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, has selected GE Healthcare Life Sciences’ off-the-shelf biomanufacturing facility, KUBio for large-scale production of its cancer monoclonal antibodies (mAbs).    http://www.genewsroom.com/press-releases/beigene-selects-ge-healthcare%E2%80%99s-shelf-biologics-factory-boost-its-manufacturing Read more

September 17, 2018 M&A, Partnerships

BeiGene Selects GE Healthcare’s Off-the-Shelf Biologics Factory to Boost its Manufacturing Capacity for Cancer Drugs

  BeiGene to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies  CHALFONT ST. GILES, UK and BEIJING, CHINA – 18 September 2018 – BeiGene, Ltd., a commercial https://www.ge.com/news/press-releases/beigene-selects-ge-healthcares-shelf-biologics-factory-boost-its-manufacturing Read more

July 31, 2018 Clinical Research/Diagn.

GE Healthcare and Lantheus Announce Start of a Phase 3 Clinical Trial of Flurpiridaz, an Investigational Agent Being Evaluated for the Detection of Coronary Artery Disease

Boston and North Billerica, MA, USA – July 31, 2018 – GE Healthcare and Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively “Lantheus”), have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease... Read more

July 25, 2018 Uncategorized

GE Healthcare’s 400th cyclotron installed at Korea Institute of Radiological & Medical Sciences (KIRAMS)

GE Healthcare’s field-proven technology and experience in cyclotron to support production of radiopharmacy and cancer diagnosis and treatment at KIRAMSGE Healthcare to share its experience and know-how in cyclotron operation through symposium to mark its 400th cyclotron installation Seoul, July 13 https://www.ge.com/news/press-releases/ge-healthcares-400th-cyclotron-installed-korea-institute-radiological-medical Read more

July 25, 2018 M&A, Partnerships

GE Healthcare’s 400th cyclotron installed at Korea Institute of Radiological & Medical Sciences (KIRAMS)

Seoul, July 13, 2018 – GE Healthcare Korea announced today it has installed its cyclotron with a complete PET radiopharmacy suite at the Korea Institute of Radiological & Medical Sciences (KIRAMS), making the nuclear medicine institute the world’s 400th cyclotron production facility under the GE brand. A cyclotron, a type of particle accelerator, accelerates charged... Read more

July 25, 2018 Uncategorized

GE Healthcare's 400th cyclotron installed at Korea Institute of Radiological & Medical Sciences (KIRAMS)

GE Healthcare’s field-proven technology and experience in cyclotron to support production of radiopharmacy and cancer diagnosis and treatment at KIRAMS GE Healthcare to share its experience and know-how in cyclotron operation through symposium to mark its 400th cyclotron installation Seoul, July 13, 2018 – GE Healthcare Korea announced today it has installed its cyclotron with... Read more

July 19, 2018 Acad, Gov/Utilities M&A, Partnerships

GE, Lagos State Government Sign Agreement on Power, Healthcare, Skills Development

Lagos, Nigeria – July 4, 2018: GE (NYSE: GE), the world’s premier digital industrial company and the Lagos State Government have agreed to pool their resources for the development of critical infrastructure in the state in the areas of Power, Healthcare and Skills Development. This was announced during the signing of a Support and Cooperation Agreement... Read more

July 16, 2018 Environ, Ag./Food & Bev Licensing, IP, and Legal Product Launch

GE Healthcare launches Omnipaque Oral Solution, a ready-to-drink iodinated contrast medium for computed tomography of the abdomen

Boston, MA, USA –July 16, 2018 – GE Healthcare is launching OmnipaqueTM (iohexol) Oral Solution in the United States, a new, ready-to-drink iodinated contrast medium that can be used to help physicians diagnose medical conditions by improving the diagnostic visualization of the abdominal gastrointestinal tract.  Omnipaque oral solution is indicated for oral use only in... Read more